STAT April 15, 2024
Jason Mast

Nearly a decade ago, venture capitalist Bob Nelsen called industry veteran Vicki Sato to pitch her on launching a large company dedicated to tackling the world’s worst pathogens. “This is a crazy idea,” Sato said.

Nelsen, managing director of ARCH Venture, had made a name and fortune off crazy ideas, but generally it was the science that sounded crazy: engineering cells to cure cancer, finding drugs to slow aging. This...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
STAT+: Doctors Without Borders challenges pharma by releasing costs for a key clinical trial
Oh, Canada: U.S. Patients Don't Want Your Health Policies
STAT+: House bill aimed at Chinese biotechs is advancing
STAT+: Pharmalittle: We’re reading about MorphoSys drug risks, an AstraZeneca admission, and more
Steep Ozempic, Wegovy prices face fresh scrutiny from officials

Share This Article